Sofosbuvir use for yellow fever: a new perspective treatment

Siqueira-Batista, Rodrigo; Bayão, Taciana de Souza; Cupertino, Marli do Carmo; Mayers, Nicholas Alfred Joseph; Gomes, Andréia Patrícia

doi:10.1080/20477724.2019.1679556

Cited by 4 publications

(4 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the GDD (Gly-Asp-Asp) motif is a highly conserved site found in flaviviruses and which has been identified as the binding site for sofosbuvir (Figure 3C) (Yap et al, 2007). This drug has shown success in both in vitro studies with dengue virus and clinical trials with yellow fever virus, thus highlighting its potential for therapeutic applications (Figure 3D) (Gan et al, 2018;Mendes et al, 2019;Siqueira-Batista et al, 2019).…”

Section: Antiviral Drugsmentioning

confidence: 99%

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Rosa-Nunes,

Lucchi,

Andreata-Santos

et al. 2023

Front. Drug Discov.

View full text Add to dashboard Cite

In the 21st Century, emergence and re-emergence of infectious diseases is significant and has an increasing importance in global concern of public health. Based on the COVID-19 pandemic and recently reported epidemics, most human pathogens originate in zoonosis. Many of such pathogens are related to viruses that have RNA genomes, which can be presented structurally as a single-strand or double-strand. During the last two decades, a timeline of major RNA viruses emergencies can be exemplified, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003, influenza A virus (H1N1) pdm09 in 2009, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Ebola virus (EBOV) in 2013–2016, Zika virus (ZIKV) in 2015 and the SARS-CoV-2 pdm19 in 2019. Even so, prophylactic or therapeutic drugs are unavailable for many RNA viruses circulating. Nonetheless, the COVID-19 pandemic brought considerable scientific advances in accelerating progress regarding prophylaxis, antiviral and drug development, and novel treatments. Regarding RNA virus diseases for humans, arboviruses play an essential and neglected role, constantly reemerging and affecting almost half of the human population, for which no drug has been licensed. Here we review the consolidated RNA viruses’ emergence and re-emergence in the 21st Century through available data. Then, we explored valuable lessons gained during the SARS-CoV-2 pandemic and focused on potential epidemiologic updates, prophylaxis, available treatments, and viral drug inhibitors. Finally, we explore arbovirus’s significance and the ongoing development of effective vaccines, antiviral drugs, and novel therapeutic approaches as strategies to control these neglected tropical diseases (NTD).

show abstract

Section: Antiviral Drugsmentioning

confidence: 99%

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Rosa-Nunes,

Lucchi,

Andreata-Santos

et al. 2023

Front. Drug Discov.

View full text Add to dashboard Cite

show abstract

“…Ponadto, zaobserwowano znaczące zmniejszenie śmiertelności związanej z YFV, zarówno poprzez ilościowe zmniejszenie zakaźnych fragmentów wirusa i zakażonych komórek, jak i w komórkach wątrobowych zwierząt [19]. W analizach in vitro komórek zakażonych wirusem ZIKV (wirus ZIKA) wykazano, że poprzez hamowanie polimerazy RNA wirusa ZIKV, sofosbuvir osiągnął skuteczność w zróżnicowanych układach komórkowych, takich jak komórki wątrobowe, neuroblastoma, komórki pnia nerwowego i organoidy mózgu [20].…”

Section: Zakażenie Flawwirusamiunclassified

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

ABRAM¹,

Patryk

ADAMUS³

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direct-acting antivirals ( DAAs) for the treatment of chronic HCV, sustained virological response (SVR) rates have begun to increase, even in treatment-resistant cases. Studies have also shown that DAAs may have applications in other viral diseases and even In the treatment of breast cancer. Aim of the study The purpouse of our study was to review scientific articles to show the efficiency and potential use of DAAs in the treatment of chronic HCV, and to identify possible directions for further research. Methods and materials We reviewed the English literature in the PubMed, using the key words: "simeprevir" ; "sofosbuvir" ; "velpatasvir" ; "telaprevir" ; "chronic hepatitis C". Results Studies have shown that the therapeutic regimens currently being designed with (DAAs) offer the possibility of treating almost the entire population with hepatitis C, while reducing side effects of interferon therapy such as increased AST, ALT activities, diarrhoea, vomiting, nausea and depression. They remain effective and tolerable, regardless of the stage of cirrhosis and associated serious co-morbidities. Analysis of studiem shows, that DAAs also show efficacy against other disease such as breast cancer, MRSA infections, SARS-CoV-2 or flavivirus infection. Conclusion All (DAAs) are effective in the treatment of patients with HCV, including cirrhosis. They result in significant improvements in prognosis and clinical outcomes. Promising results have been obtained in published data on the effect of DAAs against disease entities other than HCV, suggesting the rationale for future clinical trials to further the hypothesis of the increased potential of these drugs.

show abstract

“…The pocket is close to the active site; the designed compound 27 can bound to this allosteric pocket and inhibit the replication of DENV2 ( Figure 5 f) [ 146 ]. Sofosbuvir is a nucleotide polymerase inhibitor used in clinics to against hepatitis C virus which is distantly related with ZIKV [ 147 ]. Relevant studies of cell culture and animal have also proved that sofosbuvir inhibits viral genome replication in ZIKV infection [ 148 ].…”

Section: Structure-based Anti-flavivirus Drug Targetsmentioning

confidence: 99%

Flavivirus: From Structure to Therapeutics Development

Zhao

Wang

Cao

et al. 2021

Life

View full text Add to dashboard Cite

Flaviviruses are still a hidden threat to global human safety, as we are reminded by recent reports of dengue virus infections in Singapore and African-lineage-like Zika virus infections in Brazil. Therapeutic drugs or vaccines for flavivirus infections are in urgent need but are not well developed. The Flaviviridae family comprises a large group of enveloped viruses with a single-strand RNA genome of positive polarity. The genome of flavivirus encodes ten proteins, and each of them plays a different and important role in viral infection. In this review, we briefly summarized the major information of flavivirus and further introduced some strategies for the design and development of vaccines and anti-flavivirus compound drugs based on the structure of the viral proteins. There is no doubt that in the past few years, studies of antiviral drugs have achieved solid progress based on better understanding of the flavivirus biology. However, currently, there are no fully effective antiviral drugs or vaccines for most flaviviruses. We hope that this review may provide useful information for future development of anti-flavivirus drugs and vaccines.

show abstract

Sofosbuvir use for yellow fever: a new perspective treatment

Cited by 4 publications

References 5 publications

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

Flavivirus: From Structure to Therapeutics Development

Contact Info

Product

Resources

About